Cell News and Research

RSS

WMS, Elsevier to recognize outstanding members of wilderness medicine community

Elsevier, the leading provider of scientific, technical and medical information products and services, will present awards to outstanding members of the wilderness medicine community at this year's upcoming Wilderness Medical Society 28th Wilderness Medicine Scientific Conference & Annual Meeting, taking place in Snowmass, CO, July 29th - August 3rd.

27 Jul 2011

New preclinical data suggests microRNA-15 inhibits cardiomyogenesis

miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, announced today that new preclinical data published in the online edition of Circulation Research suggests that microRNA-15 (miR-15) inhibits cardiomyogenesis, the process whereby new heart muscle cells are formed.

27 Jul 2011

Health Canada issues notice of compliance for OCPI's SAMSCA to treat hyponatremia

Otsuka Canada Pharmaceutical Inc. (OCPI) announced today that Health Canada has issued a notice of compliance for SAMSCA (tolvaptan), the first medicine approved in Canada for the treatment of hyponatremia.

27 Jul 2011

Anavex presents data on neuroprotective evidence for lead compound for Alzheimer’s

Anavex Life Sciences Corp. is pleased to provide a summary of its second poster presentation at the Alzheimer’s Association International Conference (AAIC) held in Paris, entitled “Preclinical development of new tetrahydrofuran derivatives targeting the sigma-1 chaperone protein as neuroprotectants in Alzheimer’s disease.”

26 Jul 2011

Selexis, CSL enter commercial license agreement for therapeutic antibody

Selexis SA, a global life science company with technologies for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins announced today that CSL Limited has entered a commercial license agreement with Selexis for the preclinical development of a therapeutic antibody anticipated to enter Phase I clinical trials in 2012.

26 Jul 2011

Kadmon, Dyax enter license agreement for antibody phage display libraries

Dyax Corp. and Kadmon Corporation, LLC announced today that Dyax has granted Kadmon a non-exclusive license to Dyax's proprietary "gold-standard" antibody phage display libraries for the discovery and development of therapeutic antibodies.

26 Jul 2011

Substances found in cigarette smoke damage blood vessels' endothelial cells

A research term headed by David Bernhard from the University Department of Surgery at the Medical University of Vienna has found out that substances found in cigarette smoke lead to blood vessels' endothelial cells constantly digesting themselves.

26 Jul 2011

Late-stage prostate tumors are driven by different hormonal pathway

UT Southwestern Medical Center researchers have narrowed the potential drug targets for advanced prostate cancer by demonstrating that late-stage tumors are driven by a different hormonal pathway than was thought previously.

26 Jul 2011

BioWa, arGEN-X sign license agreement for POTELLIGENT Technology

arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody platform, announces it has signed a non-exclusive license agreement with BioWa Inc., the exclusive worldwide licensor of POTELLIGENT Technology.

26 Jul 2011

TikoMed receives FDA Orphan Drug Designation for TM-400 to treat hematological cancers

TikoMed AB, a biotechnology company focused on the development and commercialization of innovative treatments of immune diseases and transplantation therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted TM-400 Orphan Drug Designation for the mobilization of stem cells prior to stem cell transplantation treatment.

26 Jul 2011

Majority of parents unaware of medical research participation opportunities for children

One in nine adults have participated in medical research. In contrast, only one in 20 children have done so. Those are the findings of a poll earlier this year by the University of Michigan C.S. Mott Children's Hospital National Poll on Children's Health. The poll asked adults and parents about their views on medical research and past participation for themselves and their children.

26 Jul 2011

Symposium papers highlight role of oxidative stress in cardiovascular disease

Recent years have seen major advances in understanding of the health effects of oxidative stress—including its potential to cause injury to the cardiovascular system. A series of expert updates on the role of oxidative stress in heart failure, atherosclerosis, and other cardiovascular diseases appears in a special symposium in the August issue of The American Journal of the Medical Sciences, official journal of the Southern Society for Clinical Investigation.

26 Jul 2011

New potential anti-tumor agents might effectively treat mesothelioma

Researchers from the lab of Antonio Giordano, M.D., Ph.D., the Founder and Director of the Sbarro Institute for Cancer Research and Molecular Medicine, have identified new potential anti-tumor agents that might be effective in treating mesothelioma, one of the deadliest cancer tumors.

26 Jul 2011

'Core-shell' nanoparticles for effective intracellular delivery of RNAi therapeutics

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, together with collaborators at the Massachusetts Institute of Technology (MIT), announced today the publication of new paper describing discovery of "core-shell" nanoparticles for systemic delivery of RNAi therapeutics.

26 Jul 2011

GCMS, PBS Biotech sign distribution agreement for single-use bioreactors in Korea

PBS Biotech, Inc., a developer of state of the art single-use bioreactors for the fast growing biotechnology market, announced today it has signed an exclusive distribution agreement in Korea with Green Cross Medical Sciences Corp. (GCMS), a division of Green Cross Corporation, one of Korea's largest pharmaceutical firms.

26 Jul 2011

PharmaNet to assist BrainStorm in obtaining FDA approval for ALS human clinical trials

BrainStorm Cell Therapeutics Inc., an innovative developer of adult stem cell technologies and CNS therapeutics, announced today that it has signed an agreement with PharmaNet LLC, an inVentiv Health Company, to assist in the development of the protocol and IND file for submission to the FDA for approval of BrainStorm's ALS human clinical trials in the United States.

26 Jul 2011

Anesthetic agent isoflurane may treat intracerebral hemorrhage

The anesthetic agent isoflurane may be a useful treatment for intracerebral hemorrhage (ICH)—a type of stroke caused by bleeding inside the brain, reports a study in the August issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

26 Jul 2011

EMA recommends orphan drug designation for 4SC's resminostat to treat HCC

4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced that the European Medicines Agency (EMA) has recommended resminostat for designation as orphan medicinal product for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.

26 Jul 2011

Erionite in North Dakota roads may increase risk of mesothelioma

As school buses drive down the gravel roads in Dunn County, North Dakota, they stir up more than dirt. The clouds of dust left in their wake contain such high levels of the mineral erionite that those who breathe in the air every day are at an increased risk of developing mesothelioma, a type of cancer of the membranes around the lungs, new research shows.

26 Jul 2011

Researchers identify elusive gene responsible for Grey Platelet Syndrome

Researchers have identified an elusive gene responsible for Grey Platelet Syndrome, an extremely rare blood disorder in which only about 50 known cases have been reported. As a result, it is hoped that future cases will be easier to diagnose with a DNA test.

26 Jul 2011